EUROGREEN-MARITIME-SAS
8.4.2024 13:31:29 CEST | Business Wire | Press release
EuroGreen Maritime SAS (EGM), a pioneering French shipping company at the forefront of sustainable maritime solutions, announced today that it has solidified its commitment to environmental excellence by entering into a seven-year charter agreement for four vessels with the Norwegian energy company Equinor ASA (NYSE: EQNR) after being awarded the contract of the tender process initiated in December 2023. This transaction represents a significant advancement in green shipping and underscores a shared vision for a cleaner, more sustainable maritime industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408231181/en/
(Photo: Business Wire)
Innovative marine technology for a greener future
Under this landmark agreement, EGM will deliver four state-of-the-art MR IMO II Product Tankers developed in collaboration with LMG Marin France to set new standards in eco-friendly shipping, which rely on proven, commercial-utilized technologies. The vessels, scheduled for delivery starting in the first half of 2026 through 2027 and representing a value of more than US$250 million at delivery, will be built at Wuhu Shipyard Co., Ltd.'s new facility in Weihai, China. These ships will be managed on behalf of EGM by V.Ships France under this time charter agreement with Equinor upon delivery.
Each tanker features scaled, cutting-edge technology, including a MAN B&W dual-fuel methanol engine with a shaft generator complemented by a battery-hybrid power generation system, ensuring efficient and environmentally friendly operation and cold ironing shore power. In addition, the vessels are further equipped with wind assistance propulsion based on a pair of OceanWings® wingsails systems developed by the French company AYRO, enhancing their green credentials. GHG, SOx, and NOx emissions are reduced by more than 45%, 95%, and 50%, respectively, with no particles compared to conventional MR designs exceeding IMO 2030 targets.
Specifications and operations
- Vessel type: MR IMO II chemical tankers, 18 tanks, 12 segregations, MarineLINE® coating for optimal cargo operation.
- Eco propulsion: Powered by a dual-fuel methanol engine with a shaft generator.
- Wind assistance system: An innovative pair of OceanWings® by AYRO significantly reduces fuel consumption and emissions.
- Battery pack: Incorporating a large battery pack to improve power management.
- Shore power connection: To cut emissions during port operations.
- Flag and management: The four tankers will proudly fly the French flag and be managed by the esteemed ship manager, V.Ships France, of Nantes.
A strategic move for sustainable shipping
Equinor ASA plans to deploy these technologically advanced vessels into product trading activities. This initiative represents a significant step in reducing maritime operations' environmental footprint, further aligning with EGM's and Equinor's sustainability goals.
About EuroGreen Maritime (EGM)
EuroGreen Maritime is a visionary shipping company based in France, dedicated to leading the transition towards more sustainable maritime practices. Through innovation and collaboration, EGM is committed to reducing the environmental impact of shipping and promoting cleaner seas for future generations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408231181/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom